Overview

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen